Gilead Sciences paid in excess of $400 million to acquire a preclinical oncology program from Sprint Bioscience that targets TREX1, an enzyme involved in nucleic acid sensing and tumor immune evasion. The deal adds a TREX1‑focused asset to Gilead’s expanding oncology portfolio as the company seeks new immuno‑oncology mechanisms. Gilead said the acquisition complements its prior investments in tumor biology and immune modulation and will be integrated into internal preclinical pipelines for target validation and IND enabling studies. Sprint retains technology rights in other areas per the transaction terms disclosed. The purchase underscores larger pharma’s strategy of buying late‑stage preclinical programs to fill oncology pipelines quickly and signals continued investor appetite for innate immune‑targeted cancer approaches.